Relapse in Melioidosis: Incidence and Risk Factors

• Main Authors: Y. Suputtamongkol, W. Chaowagul, D. A.B. Dance, A. Rajchanuvong, J. Pattara, N. J. White
• Other Authors: Mahidol University
• Format: Article
• Published: 2018
• Subjects: Medicine
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/22800

From 1986 to 1991, 602 patients with melioidosis were seen in Sappasitprasong Hospital, Ubon Ratchatani, Thailand. The in-hospital mortality was 42%. Of 118 adult patients followed long-term, 27 (23%) had culture-proven relapses of melioidosis (3 relapsed twice), a relapse rate of 15% (95% confidence interval [CI], 11–22) per year. The median time from discharge to relapse was 21 weeks (range, 1–290). In 44% of patients, relapses included septicemia, and 27% died. Patients with severe disease (multiple foci of infection or septicemia) relapsed 4.7 times (95% Cl, 1.6–14.1) more frequently than patients with localized melioidosis. Underlying disease was not a risk factor, but initial parenteral treatment with ceftazidime reduced the risk of relapse 2-fold (95% CI, 1.1–3.4). Relapses were 3.3 (95% CI, 1.4–9.0) times more frequent following short-course (⩾8 weeks) oral coamoxiclav than after the oral combination regimen of chloramphenicol, doxycycline, and cotrimoxazole. Longer oral treatment with either reduced relapse 1.6-fold (95% CI, 1.2–1.9). The optimum choice and duration of antibiotic treatment to prevent relapse in melioidosis remain to be determined. © 1993 by The University of Chicago.